Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
08
2020
accepted:
28
12
2020
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Hereditary breast cancer accounts for 5-10% of all breast cancer cases. So far, known genetic risk factors account for only 50% of the breast cancer genetic component and almost a quarter of hereditary cases are carriers of pathogenic mutations in BRCA1/2 genes. Hence, the genetic basis for a significant fraction of familial cases remains unsolved. This missing heritability may be explained in part by Copy Number Variations (CNVs). We herein aimed to evaluate the contribution of CNVs to hereditary breast cancer in Tunisia. Whole exome sequencing was performed for 9 BRCA negative cases with a strong family history of breast cancer and 10 matched controls. CNVs were called using the ExomeDepth R-package and investigated by pathway analysis and web-based bioinformatic tools. Overall, 483 CNVs have been identified in breast cancer patients. Rare CNVs affecting cancer genes were detected, of special interest were those disrupting APC2, POU5F1, DOCK8, KANSL1, TMTC3 and the mismatch repair gene PMS2. In addition, common CNVs known to be associated with breast cancer risk have also been identified including CNVs on APOBECA/B, UGT2B17 and GSTT1 genes. Whereas those disrupting SULT1A1 and UGT2B15 seem to correlate with good clinical response to tamoxifen. Our study revealed new insights regarding CNVs and breast cancer risk in the Tunisian population. These findings suggest that rare and common CNVs may contribute to disease susceptibility. Those affecting mismatch repair genes are of interest and require additional attention since it may help to select candidates for immunotherapy leading to better outcomes.
Identifiants
pubmed: 33503040
doi: 10.1371/journal.pone.0245362
pii: PONE-D-20-26953
pmc: PMC7840007
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245362Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Bioinformatics. 2012 Feb 15;28(4):470-8
pubmed: 22199393
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Hered Cancer Clin Pract. 2014 May 24;12(1):15
pubmed: 24955146
PLoS One. 2012;7(10):e44294
pubmed: 23056178
Tumour Biol. 2016 Jan;37(1):151-62
pubmed: 26577857
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Genome Med. 2009 Jun 16;1(6):62
pubmed: 19566914
Int J Mol Cell Med. 2015 Spring;4(2):103-8
pubmed: 26261799
Genome Res. 2012 Feb;22(2):208-19
pubmed: 22156295
Chin J Cancer. 2016 Jun 07;35(1):51
pubmed: 27267075
Cytogenet Genome Res. 2008;123(1-4):183-7
pubmed: 19287154
Future Oncol. 2012 Apr;8(4):441-50
pubmed: 22515447
Bioinformatics. 2012 Nov 1;28(21):2747-54
pubmed: 22942019
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
PLoS Genet. 2012;8(6):e1002734
pubmed: 22737080
Gynecol Oncol. 2019 May;153(2):452-462
pubmed: 30733081
Br J Cancer. 1999 Dec;81(8):1410-8
pubmed: 10604741
J Natl Cancer Inst. 2013 Apr 17;105(8):573-9
pubmed: 23411593
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Expert Rev Mol Diagn. 2013 May;13(4):349-65
pubmed: 23638818
Nat Methods. 2012 Apr 27;9(5):459-62
pubmed: 22543379
Breast Cancer Res. 2012 Feb 07;14(1):R24
pubmed: 22314128
BMC Cancer. 2012 Jun 18;12:257
pubmed: 22708928
N Engl J Med. 2009 Nov 19;361(21):2046-55
pubmed: 19776401
Pharmacogenomics. 2011 Nov;12(11):1535-43
pubmed: 21961651
PLoS One. 2013 Aug 13;8(8):e71802
pubmed: 23967248
Nat Genet. 2015 Aug;47(8):872-7
pubmed: 26121086
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
J Transl Med. 2018 Jun 7;16(1):158
pubmed: 29879995
Int J Mol Sci. 2017 Nov 22;18(11):
pubmed: 29165356
Oncotarget. 2018 Sep 14;9(72):33648-33655
pubmed: 30263092
Nat Rev Genet. 2015 Mar;16(3):172-83
pubmed: 25645873
Am J Hum Genet. 2010 May 14;86(5):749-64
pubmed: 20466091
Nucleic Acids Res. 2017 Jan 4;45(D1):D833-D839
pubmed: 27924018
Hum Mutat. 2014 Jul;35(7):899-907
pubmed: 24599517
J Appl Genet. 2017 Nov;58(4):449-457
pubmed: 28963714
Bioinformatics. 2014 Oct;30(19):2811-2
pubmed: 24930139
Database (Oxford). 2014 Mar 07;2014:bau015
pubmed: 24608173
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Br J Cancer. 2003 Oct 20;89(8):1502-7
pubmed: 14562023
Cancer Genet. 2015 Sep;208(9):448-54
pubmed: 26271414
Cancer Treat Rev. 2015 Jan;41(1):1-8
pubmed: 25467110
Genet Med. 2018 Oct;20(10):1167-1174
pubmed: 29345684
Bioinformatics. 2012 Jul 1;28(13):1805-6
pubmed: 22543366
PLoS One. 2014 Feb 20;9(2):e89302
pubmed: 24586676
Breast Cancer Res Treat. 2010 May;121(1):195-202
pubmed: 19760040
Cancer Genet. 2017 Jan;210:22-27
pubmed: 28212807
Nucleic Acids Res. 2018 Jul 2;46(W1):W545-W553
pubmed: 29860484
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Mol Biol Rep. 2012 Dec;39(12):10531-9
pubmed: 23053953
J Mol Diagn. 2017 Nov;19(6):809-816
pubmed: 28822785
Nat Commun. 2013;4:1627
pubmed: 23535648
Eur J Hum Genet. 2016 May;24(5):652-9
pubmed: 26306646
Int J Oncol. 2018 Jun;52(6):2069-2078
pubmed: 29620155
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Int J Cancer. 2021 Jan 7;:
pubmed: 33423300
Eur J Hum Genet. 2017 Jun;25(6):719-724
pubmed: 28378820
Carcinogenesis. 2013 Oct;34(10):2240-3
pubmed: 23715497
Cancer Lett. 2000 May 29;153(1-2):113-20
pubmed: 10779639
Hum Mutat. 2011 Sep;32(9):1063-71
pubmed: 21618646
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nature. 2020 Jul;583(7814):83-89
pubmed: 32460305
Mol Carcinog. 2012 Oct;51 Suppl 1:E142-50
pubmed: 22392686
Nucleic Acids Res. 2014 Jan;42(Database issue):D986-92
pubmed: 24174537
Oncogene. 2017 Mar 30;36(13):1793-1803
pubmed: 27694902
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Genet Med. 2017 Jun;19(6):667-675
pubmed: 28574513
Bioinformatics. 2018 Oct 15;34(20):3572-3574
pubmed: 29669011
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2016 Nov 15;7(46):74979-74986
pubmed: 27602762
Lancet Oncol. 2009 Mar;10(3):267-77
pubmed: 19261255
Oncotarget. 2017 Jul 19;8(44):76357-76374
pubmed: 29100317
Breast Cancer Res. 2017 Mar 16;19(1):30
pubmed: 28302160
Sci Rep. 2017 Nov 7;7(1):14621
pubmed: 29116104